Ionis (IONS) partner Novartis (NVS) shared in their year-end earnings report that Phase 3 pelacarsen data is now expected in the first half of 2026 with subsequent regulatory submissions in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback